

Hemophilia A

**A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A**

**Trial Status**  
Recruiting

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT05987449 2023-503906-35-00  
WP44714

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

Study WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter, multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. The aim is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of NXT007.

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT05987449 2023-503906-35-00 WP44714**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
Male

**Age**  
>=12 Years & <= 59 Years

**Healthy Volunteers**  
No

---